Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Moderna Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Moderna şirketinin toplam hissedar öz sermayesi $11.7B ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $15.7B ve $4.0B dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.49b
Eşitlik	US$11.71b
Toplam yükümlülükler	US$3.97b
Toplam varlıklar	US$15.68b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MRNA 'nin kısa vadeli varlıkları ( $9.7B ) kısa vadeli yükümlülüklerini ( $2.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: MRNA şirketinin kısa vadeli varlıkları ( $9.7B ) uzun vadeli yükümlülüklerini ( $1.6B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MRNA borçsuzdur.

Borcun Azaltılması: MRNA un 5 yıl önce borcu yoktu.

Borç Kapsamı: MRNA un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: MRNA şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Moderna Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 16%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin